SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-18-013588
Filing Date
2018-03-15
Accepted
2018-03-15 14:54:04
Documents
11
Effectiveness Date
2018-03-15

Document Format Files

Seq Description Document Type Size
1 FORM 8-K s002111x2_8k.htm DEFA14A 50851
2 EXHIBIT 4.1 s002111x2_ex4-1.htm EX-4.1 191965
3 EXHIBIT 10.1 s002111x2_ex10-1.htm EX-10.1 992934
4 EXHIBIT 10.2 s002111x2_ex10-2.htm EX-10.2 136767
5 EXHIBIT 10.3 s002111x2_ex10-3.htm EX-10.3 202001
6 EXHIBIT 10.4 s002111x2_ex10-4.htm EX-10.4 79945
7 EXHIBIT 99.1 s002111x2_ex99-1.htm EX-99.1 30527
8 EXHIBIT 99.2 s002111x2_ex99-2.htm EX-99.2 154359
9 EXHIBIT 99.3 s002111x2_ex99-3.htm EX-99.3 4971
10 s002111_ex991-image1.jpg GRAPHIC 9242
11 s002111_ex991-image2.jpg GRAPHIC 92305
  Complete submission text file 0001140361-18-013588.txt   1985384
Mailing Address 2855 GAZELLE CT CARLSBAD CA 92010
Business Address 55 CAMBRIDGE PARKWAY SUITE 100 CAMBRIDGE MA 02142 760-603-2732
AKCEA THERAPEUTICS, INC. (Filer) CIK: 0001662524 (see all company filings)

IRS No.: 472608175 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38137 | Film No.: 18692137
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1